Ben Nacev, MD PhD
@bennacev.bsky.social
I am a physician-scientist and sarcoma medical oncologist. My lab studies how alterations in the epigenome influence cancer biology. Our goal is to use that knowledge to find better ways to help patients. nacevlab.com
Between this and the recent pembro trial it has been a good few months for KS clinical data
June 12, 2025 at 1:01 PM
Between this and the recent pembro trial it has been a good few months for KS clinical data
I was excited about these data for CDK4/6 inhibition in KS. > 70% PR. ascopubs.org/doi/10.1200/...
A phase I/II study of abemaciclib, a CDK4/6 inhibitor, in participants with HIV-associated and HIV-negative Kaposi sarcoma.
11505Background: Kaposi sarcoma (KS), caused by Kaposi sarcoma herpesvirus (KSHV), is a multicentric
angioproliferative tumor seen in people with and without HIV. Abemaciclib (abema)
is an oral cyclin...
ascopubs.org
June 11, 2025 at 11:33 PM
I was excited about these data for CDK4/6 inhibition in KS. > 70% PR. ascopubs.org/doi/10.1200/...